Experimental pill aims to supercharge radiation against deadly brain tumors
NCT ID NCT06359379
Summary
This study tested whether adding an oral medication called ropidoxuridine to standard radiation treatment could better control an aggressive type of brain cancer called glioblastoma. The trial involved 30 adults with newly diagnosed tumors that are typically resistant to standard chemotherapy. The goal was to see if the pill makes cancer cells more vulnerable to radiation, potentially slowing tumor growth and extending survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA, IDH-WILDTYPE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212, United States
-
John Theurer Cancer Center at the Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, 20007, United States
-
Miami Cancer Institute
Miami, Florida, 33176, United States
-
University of Virginia
Charlottesville, Virginia, 22903, United States
Conditions
Explore the condition pages connected to this study.